Quantitative in situ interactomics to complement genomics, transcriptomics, and proteomics
Multi-omics approaches generate vast molecular datasets yet often lack direct information on functional protein interactions within intact tissues. Expression alone does not fully reflect interaction, activation, or clinical relevance. This is especially relevant when multi-omics points to candidate networks, but functional validation in tissue remains the missing layer.
QF-Pro® is an in situ interactomics technology that enables direct, quantitative measurement of protein–protein interactions (PPIs) and post-translational modifications (PTMs) in tissue. By preserving spatial context, QF-Pro® captures functional molecular activity where it naturally occurs.
Importantly, QF-Pro® supports multiplexed functional readouts within the same sample, allowing the assessment of multiple interactions and signalling events, providing a network-level view in tissue.
Altogether, QF-Pro® complements other multi-omics techniques by adding the ‘‘missing’’ functional layer, helping translate multi-omics data into biologically and clinically meaningful insights.

QF-Pro® complements expression-based tissue profiling by adding a quantitative interaction and activation layer directly in situ.

Key benefits
- Functional validation of multi-omics hypotheses directly in situ
- Strong complement to spatial proteomics and tissue-based discovery workflows
- Quantitative PPIs and PTMs readouts in intact tissue context
- Multiplexed detection of biomarkers for adding a network of interactions
- Clinically relevant, reproducible, and standardized measurements suitable for cohort-level comparisons
Validated biomarkers:
Protein-protein interactions (PPIs)
- PD-1/PD-L1
- CTLA-4/CD80
- IGIT/CD155
- LAG3/MHC-
- IITIM3/Gal9
- OX40-OX40L
- CD69/Gal1
- HER2/HER3
- HER3/EGFR
- HER2/EGFR
- Podocalyxin/Beta-catenin
- Podocalyxin/NHERF-1
- PD-1/SHP-2
- Cyclin E/CDK2
- Beta-catenin/E-cadherin
- PKB/PDK1
Post-translational modifications (PTMs)
- Akt/PKB activation state (pT308)
- EGFR activation state (pY1068)
- Rb activation state (pS807/811)
- STAT3 activation state (pY705, pS727)

Meet HAWK Biosystems in Germany: Summer 2026
Together with HAWK Biosystems, we will visit multiple cities to:
- Present QF-Pro® in research facilities
- Attend scientific events
- Connect with researchers working on complementary multi-omics and tissue-based biology

